异基因移植后输注白血病特异性供者T细胞治疗AML/MDS的临床效果
本研究针对异基因造血干细胞移植后AML/MDS复发难题,从29名供者制备针对PRAME、WT1、Survivin和NY-ESO-1多抗原的白血病特异性T细胞(mLSTs),体外可选择性杀伤白血病抗原脉冲细胞而不伤正常细胞。25例受试者接受递增剂量(0.5-10×10^7 cells/m^2)输注,耐受良好,未见>2级急性或广泛慢性GVHD,中位无白血病生存和总生存未达到(随访1.9年),活动性疾病组见1例完全缓解和1例部分缓解。
要点
- mLSTs体外选择性识别并杀伤白血病抗原脉冲细胞,对受者正常细胞无活性。
- 25例受试者输注mLSTs耐受良好,未见>2级急性或广泛慢性GVHD。
- 随访1.9年时中位无白血病生存和总生存未达到,活动性疾病组见客观缓解。
核心结论
- mLSTs用于HCT后AML/MDS的预防和治疗是安全的且有前景。
研究设计与样本
- 从29名HCT供者制备白血病抗原特异性T细胞产品。
- 25例入组受试者接受递增剂量mLSTs输注(0.5至10×10^7 cells/m^2),其中17例高复发风险、8例复发疾病。
主要发现
- mLSTs体外选择性识别并杀伤白血病抗原脉冲细胞,对受者正常细胞无活性。
- 输注耐受良好,未见>2级急性或广泛慢性GVHD。
- 观察到体内抗白血病效应,随访1.9年时中位无白血病生存和总生存未达到。
- 活动性疾病队列见客观缓解:1例完全缓解和1例部分缓解。
临床怎么用
- HCT后AML/MDS患者可考虑输注供者来源白血病特异性T细胞以增强GVL并减少GVHD。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Relapse after allogeneic hematopoietic stem cell transplantation (HCT) is the leading cause of death in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Infusion of unselected donor lymphocytes (DLIs) enhances the graft-versus-leukemia (GVL) effect. However, because the infused lymphocytes are not selected for leukemia specificity, the GVL effect is often accompanied by life-threatening graft-versus-host disease (GVHD), related to the concurrent transfer of alloreactive lymphocytes. Thus, to minimize GVHD and maximize GVL, we selectively activated and expanded stem cell donor-derived T cells reactive to multiple antigens expressed by AML/MDS cells (PRAME, WT1, Survivin, and NY-ESO-1). Products that demonstrated leukemia antigen specificity were generated from 29 HCT donors. In contrast to DLIs, leukemia-specific T cells (mLSTs) selectively recognized and killed leukemia antigen-pulsed cells, with no activity against recipient's normal cells in vitro. We administered escalating doses of mLSTs (0.5 to 10 × 107 cells per square meter) to 25 trial enrollees, 17 with high risk of relapse and 8 with relapsed disease. Infusions were well tolerated with no grade >2 acute or extensive chronic GVHD seen. We observed antileukemia effects in vivo that translated into not-yet-reached median leukemia-free and overall survival at 1.9 years of follow-up and objective responses in the active disease cohort (1 complete response and 1 partial response). In summary, mLSTs are safe and promising for the prevention and treatment of AML/MDS after HCT. This trial is registered at www.clinicaltrials.com as #NCT02494167.
引用
- Lulla PD, Naik S, Vasileiou S, et al. Clinical effects of administering leukemia-specific donor T cells to patients with AML/MDS after allogeneic transplant. Blood. 2021. PMID: 33270816. doi:10.1182/blood.2020009471
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。